Abstract | OBJECTIVE:
Irinotecan is a potent inhibitor of deoxyribonucleic acid topoisomerase 1 and the weekly schedule of 100-125 or 350 mg/m(2) administration on Day 1 every 3 weeks is recommended for recurrent small cell lung cancer. However, severe gastrointestinal toxic effects and myelosuppression are often observed in this dose setting. We conducted a retrospective study to evaluate the efficacy and safety of low-dose irinotecan monotherapy (60 mg/m(2) on Days 1, 8 and 15 every 4 weeks) as second-line chemotherapy for small cell lung cancer. METHODS: The medical charts of small cell lung cancer patients who had received second-line chemotherapy at the National Cancer Center Hospital East between April 2003 and June 2012 were reviewed. Consecutive 57 patients who were treated with low dose of irinotecan (60 mg/m(2) on Days 1, 8 and 15 every 4 weeks) were analyzed in this study. RESULTS: Median age was 70 years (range, 51-83). Fifty-two (91%) were male, 36 (63%) had an Eastern Cooperative Oncology Group performance status 0-1 and 26 (46%) were sensitive relapse. The median number of chemotherapy cycles was 2. The objective response rate was 32% (95% confidence interval: 20-45%).The median progression-free survival and the median overall survival were 2.9 months (95% confidence interval: 1.9-3.4 months) and 5.3 months (95% confidence interval: 3.6-7.6 months), respectively. The incidence of Grade 3/4 neutropenia, diarrhea and nausea/ vomiting was 21, 4 and 5%, respectively. CONCLUSIONS:
|
Authors | Masahiro Morise, Seiji Niho, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto, Hironobu Ohmatsu, Yuichiro Ohe |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 44
Issue 9
Pg. 846-51
(Sep 2014)
ISSN: 1465-3621 [Electronic] England |
PMID | 25057092
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: [email protected]. |
Chemical References |
- Antineoplastic Agents, Phytogenic
- Irinotecan
- Camptothecin
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Phytogenic
(administration & dosage, adverse effects, therapeutic use)
- Camptothecin
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Diarrhea
(chemically induced)
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Humans
- Infusions, Intravenous
- Irinotecan
- Kaplan-Meier Estimate
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Medical Records
- Middle Aged
- Nausea
(chemically induced)
- Neoplasm Recurrence, Local
(drug therapy)
- Neutropenia
(chemically induced)
- Retrospective Studies
- Severity of Illness Index
- Small Cell Lung Carcinoma
(drug therapy, pathology)
- Treatment Outcome
- Vomiting
(chemically induced)
|